Abiomed (ABMD), a leading provider of novel percutaneous cardiac assist devices that are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart, has seen its revenues increased by more than 100% in the last four years.
Abiomed's Impella range of heart pumps has enormous growth potential in the treatment of cardiovascular diseases. Although the stock price of Abiomed has more than doubled itself in the last one year, I believe there is still some room for price appreciation over the medium term. In this article I will analyze the future prospects of Impella, Abiomed's lead product and its potential impact on...
Only subscribers can access this article, which is part of the PRO research library covering 3,553 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: